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The aim of this review is to present an update on the current knowledge within this field of ocular drug delivery. 
There is a lots of route of drug delivery, but today one of them, the ocular drug delivery system becomes the most 
compulsive and attractive attempt in front of pharmaceutical scientists.  Ocular drug delivery has always been a 
formidable task in the area of pharmaceutical research due to distinctive structure and function of the eye. Different 
attempt in ocular drug delivery have been made to enhance the bioavailability and to increase the contact time of 
topically applied drugs to the eye. In an ophthalmic dosage form the less bioavailability is due to the tear production, 
achieving less absorption, short term residence time, and less permeability of corneal epithelium. Immediate pre-
corneal elimination is a biggest problem in ocular drug delivery. In order to solve this problem, researchers 
developed a new system; in-situ gel forming system. This formulation undergoes phase transition in the eye to form 
gel, thus prolonging the precorneal contact time which will result in enhance ocular bioavailability for prolonged 
therapeutic action ointment, suspensions and gelled systems are also used. 
Keywords: Ocular drug delivery, precorneal, bioavailability.  
Introduction 
 
Ocular drug delivery is most compulsive and 
demanding delivery system in front of the 
pharmaceutical scientist. The unique structure, 
function, and biochemistry of the eye provide this 
organ highly impermeable to foreign substances. An 
important searching to the formulator is to overcome 
the protective barriers of the eye without causing long 
term tissue damage[1]. These types of barriers are 
highly affecting the bioavailability of ophthalmic 
drugs. In ophthalmic drug delivery system, the rapid 
and extensive elimination is the main problem of 
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This difficulty results in huge loss of drug. Only a less 
amount of drug penetrates the corneal layer and passes 
to inner tissue of eye. The main division of drug loss 
contain lachrymal drainage and drug dilution by tears. 
This satisfaction reduces the ocular bioavailability and 
conduct to undesirable side effect and toxicity[2]. 
To optimize ophthalmic drug delivery systems the 
following characteristics are required:   
 Sterility 
  Isotonicity 
  A good corneal penetration  
 Minimum protein binding 
 Less drainage tendency 
 Buffer/ pH adjustment 
 A continued contact time of drug with corneal 
tissue 
 Easiness in installation and removal. 
 A non-irritative form 
 Good rheological properties[3-5] 
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Physiology of sight 
Light waves travel at a speed of 300 000 kilometres 
(186 000miles) per second. Light is reflected into the 
eyes by objects within the field of vision. White light is 
a combination of all the colours of the visual spectrum 
(rainbow), i.e. red, orange, yellow, green, blue, indigo 
and violet. This is demonstrated by passing white light 
through a glass prism which bends the rays of the 
different colours to a greater or lesser extent, 
depending on their wavelength[6]. In the field of visual 
spectrum red colour light has the longest wavelength 
and violet colour has the shortest wavelength.This 
range of colour is the spectrum of visible light. In a 
rainbow, white light from the sun is broken up by rain 
drops, which act as prisms and reflectors[7].The main 
function of the eye is to receive the light which is 
converted into visual image on the retina from where it 
is translated into a correct picture by the involvement 
of visual centres in the brain. In each hemisphere of the 
brain of optic nerve fibres from the eyes reach the optic 
lobe which contains the visual centres. Impulses to 
neurons in these lobes register the image. When light 
falls on the rhodopsin containing cells of retina, the 
rhodopsin molecules split into separate retinene and 
opsin component and a nerve impulse is produced at 
the same time. In the darkness of the eyeball and with 
the help of respiratory energy, retinene and opsin 
recombine again. This recombination generates the 
image. In very intense light and in the absence of 
vitamin A, this reaction does not take place, therefore 
image formation becomes impossible. In a way image 
formation is a chemical reaction which needs moderate 
light to act as a catalyst. An object to be pictured on the 
retina forms a series of points corresponding to rods 
and cones and the image is the sum total of all these 
points. Although there forms an inverted image like 
that in a camera, yet the visual centres of the brain do 
the job of giving a correct orientation to the inverted 




Fig 1: Structure of Eye[3] 
Disease of eye 
Myopia (Near Sightness) 
In this disorder, a person can only see near objects and 
has difficulty in having a correct sharp focus of the 
distant objects because the eyeball is oblong or 
elongated so that the distance between the lens and the 
retina is more than required. The image falls short of 
reaching the retina and a person experiences a blurred 
image. Spectacles with concave lenses are needed to 
extend the focus to the retina 
Hypermetropia (Far Sightedness) 
This defect is reverse of myopia as the eyeball is 
shorter than its normal size, whereby the focus of 
image extends beyond retina because it is nearer to the 
lens instead of being at its original position in the 
normal eye. A person with this defect has difficulty in 
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seeing the near objects but can clearly see the distant 
objects. Spectacles with convex lenses are needed to 
restore normal vision. 
Astigmatism 
This disorder does not permit a person to see clearly 
the objects irrespective of their distance from the eye 
due to the uneven curvature of the lens. Accordingly, 
uneven convex lenses are needed to bring the focus to 
the right place on the retina. Such lenses are made by 
girding them as per requirements. 
Presbyopia 
Presbyopia is generally a disorder of old age when the 
lens are starts losing its elasticity so that it fails to from 
the images to near objects while distant vision is 
normal. A person suffering from this defect has to keep 
the object or a paper as far away from him as required 
improving visibility. Convex lenses are needed for 
correcting the disorder. 
 
Cataract 
Cataract is also an abnormality of the lens in which it 
becomes partially or completely opaque so that no light 
gets into the eye. The commonest reason is ageing 
while injury, heredity and diabetes, etc. are other 
possible reasons. It is the commonest disorder known 
as sfaid motia which can be cured by removing the 
defective lens[9] 
Glaucoma 
Glaucoma is another common cause of blindness. In 
this disorder of the eye, there is failure of the drainage 
of liquid from the anterior chamber as a result of 
which, more than the required amount accumulates in it 
which cause pressure on the optic nerve and retina. 
Increased pressure hinders the normal supply of blood 
and nutrients. However, the disease is curable when 
detected and attended early. It is also known as kala 
motia which is common in older persons[10]. 
 
 
Fig 2:Normal eye and Glucoma 
 
Keratitis 
Keratitis is the inflammation of cornea which may also 
get damaged by injury or serious infection. Corneal 
grafting or replacement with a normal cornea from the 
donor is a part of the publicity that is given to the 
phenomenon of the donation of eyes after death. 
Conjuctivitis 
One often hears of epidemic of this disease in which 
eyes become red and there is continuous watery 
discharge from them. It is caused by infection of the 
conjunctiva which is curable by easily available 
formulations. Photophobia or intolerance to light is 




It is also a common disorder of the eyes due to viral 
infections of the conjuctiva that can assume epidemic 
proportions when allowed to spread due to carelessness 
in treatment[11]. 
Dry Eye 
Dry eye is a condition in which a person doesn’t have 
enough quality tears to lubricate and nourish the eye. If 
the composition of tears is changed, or an inadequate 
volume of tears is produced, the symptom of dry eye 
will result. Dry eye conditions are not just a cause for 
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Ocular Drug Delivery System 
Ophthalmic dosage formulations are classified as 
conventional and non – conventional (newer) drug 
delivery system. Various formulation like In situ 
gelling, use of mucoadhesive polymers, polymer 
coated nano-particles and microspheres, micro 
emulsion and liposomal formulation are used[6]. There 
are most frequently available ophthalmic preparation 
such as drops and ointments about 70 % of the eyes 
dosage formulations in the market. These formulations 
delay the elimination of active ingredient from eye, 
also improve bioavailability of the drug and increase 
corneal penetration of drug molecule[13].The primary 
approaches in the design of control release ocular drug 
delivery system attempt to slow down the drainage of 
drug by tear flow. The conventional and novel drug 
delivery system are explained as below[11] 
 
 
Fig 3:Different formulations for eye 
 
Conventional Ophthalmic Systems 
Most of the  topically administered dose is lost due to 
reflux blinking and only 20% of instilled dose is 
retained in the precorneal pocket, conventional ocular 
drug delivery system have some limitations along with 
them like poor bioavailability, less resistance time of 
drug in pre corneal area[11]. Some of the important 
types of conventional ophthalmic preparations are: 
Solutions  
 Drugs which are active at eye or eye surface are 
widely administered in the form of Solutions. 
Ophthalmic solutions are sterile solution and they are 
free from foreign particle[14]. Solutions are widely 
used dosage forms for topical delivery of therapeutics 
to the eye[15]. In an ocular drug delivery system the 
major factor  that affect the formulations are solubility, 
ocular toxicity, pka,  ph effect, tonicity, buffer 
capacity, viscosity, compatibility with other ingredients 
in the formulation, preservatives to be used, comfort 
when instilled into the eye[5]. 
Advantages 
1 Simplicity of large scale manufacture  
2 convenience and 
3 Usually do not interfere with vision of patient 
 Disadvantages  
1  Solution having very short time interval so its 
rapid precorneal elimination from the eye. 
2  The retention of a solution in the eye is influenced 
by viscosity, hydrogen ion concentration and the 
instilled volume. 
3  75% is lost via nasolacrimal drainage so having 
poor bioavailability.  
4  Occular drug delivery having non sustained 
action. 
5 To be administered at frequent intervals. 
 
Suspensions 
Suspension may be defined as dispersion of finely 
divided insoluble API in an aqueous solvent consisting 
of a suitable suspending and dispersing agent. An 
ocular topical drop these are another class of non – 
invasive drug carrier system. Ophthalmic suspension 
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improves the bioavailability because it retains in 
precorneal pocket and thereby improve drug contact 
time and duration of action relative to drug 
solution[13]. These are more complex when compare 
the eye drop[15]. 
An ophthalmic suspension contains many excipients 
like suspending agents, wetting agents, buffers and 
preservatives. Suspending agents are used to avoid the 
sedimentation and improve rheological property of a 
suspension. Generally ophthalmic suspension used 
suspending agents are includes cellulosic derivatives 
such as methyl cellulose, caboxy methyl cellulose, and 
hydroxyl propyl methyl cellulose, synthetic polymers 
such as carbomers, poloxamers, and polyvinyl alcohol. 
Wetting agents are used to decreases the contact angle 
between the solid surface and the wetting liquid. 
Generally used wetting and solubilizing agents are 
Benzalkonium chloride, Benzethonium chloride, 
Cetylpyridinium chloride, Nonoxynol 10, Octoxynol 9, 
Poloxamer, Polyoxyl 50 stearate, Polyoxyl 20 
cetostearyl ether, Polyoxyl 40 stearate[14].  
Emulsion 
Ophthalmic emulsions are generally dispersions of oily 
droplets in an aqueous phase, there should be no 
evidence of breaking or coalescence[16]. An emulsion 
based formulation has an advantage to improve 
solubility and bioavailability of drugs. Two types of 
emulsion are there which are commercially used as 
vehicles for active pharmaceuticals: oil in water (o/w) 
and water in oil (w/o) emulsion systems. Because of 
less irritation and better ocular tolerance o/w emulsion 
is common and widely preferred over w/o system for 
ophthalmic drug delivery[13]. The advantage of this 
type of formulations is prolonging release of drug from 
vehicle. Patient non compliance is the demerits of 
emulsion[17]. 
Eye drops: Eye drops are saline-containing drops used 
as an ocular route to administer[17].Eye drops are used 
only for anterior segment disorders of eyes because 
insufficient drug concentrations reached in the 
posterior tissues using ocular drug delivery system. 
Hydrogen ion concentration, osmolality, viscosity and 
instilled volume are some property that effect retention 
of a solution in the eye. Only less than 5% of the drug 
is absorbed after administration of the drug into eye, 
major fraction of the administered drug get washed 
away with the lachrymal fluid or absorbed systemically 
in the nasolacrimal duct and pharyngeal sites[6]. The 
important constituents present in these may be 
antihistamines, steroids which are commonly used in 
glaucoma patients, beta receptor blockers, 
prostaglandins, topical anaesthetics and many others. 
Some eye drops marketed do not contain any active 
pharmaceutical agent and they are used only for a 
lubricating and tear replacement purpose[18].  
Recent work done in eye drops New Eye Drops Can 
Dissolve Cataracts with No Need for Surgery Zhang 
and his research team went on to develop eye drops 
that contained lanosterol as a drug treatment for 
cataracts[17]. 
Ointment 
 Ophthalmic ointments are the semi solid dosage form 
and  usually prepared by using mixtures of semisolid 
and solid hydrocarbons like paraffin which have a 
melting point or softening point is nearby to body 
temperature and are non irritating to the eye[5]. Using 
ophthalmic ointment vehicle enhance contact time with 
the external ocular surface can be achieved but, some 
demerits like, blurring of vision can limits its use. 
Pilopine HS gel containing pilocarpine was used to 
provide sustain action over a period of 24 hours. A 
number of workers reported that ointments vehicles can 
improve the corneal contact time of many drugs 
administered by topical ocular route, thus prolonging 
duration of action and enhancing ocular bioavailability 
of drugs[19]. Ophthalmic ointments are applied 
externally on the surface of eye. This dosage form less 
preferred as compared to the emerging dosage 
ophthalmic forms because occurrence of some patients 
irritation and blurred vision[18]. 
Sprays 
 Eye spray is mainly used for pupil dilation or for 
cycloplegics (paralysis of the cilliary muscle of the 
eye) examination. Even ophthalmic sprays are not 
commonly used, but some patients with mydriatics or 
cycloplegics use alone or in combination in the form of 
eye spray[20] 
Viscous Solution  
 These types of solutions are prepare in laboratory scale 
by adding some polymer and enhancing the viscosity 
of the eye preparations ,so that in the precorneal area 
the residence time could be increased hence a greater 
transcorneal penetration of the drug into the anterior 
chamber. In terms of improvement in bioavailability it 
has minimal effects in humans. The viscous solution is 
prepared by adding some viscosifying agents like 
cellulose, polyacrylic acid. Carbomer, Xanthan gum 
also holds an important place in increasing viscosity of 
these agents18. Some other polymers used are 
methylcellulose, polyvinyl alcohol (PVA), 
polyvinylpyrrolidone (PVP), hydroxyethylcellulose, 
hydroxypropyl methylcellulose (HPMC), and 
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hydroxyl-propylcellulose.  Natural polymers such as 
HA, veegum, alginates, xanthan gum, gelatin, acacia., 
and tragacanth can also be used as viscosity enhancers. 
However, these suffer the drawback of harboring 
bacteria and fungi[5]. 
Gels 
Ophthalmic gels are composed of mucoadhesive 
polymers that provide localized delivery of an active 
ingredient to the eye.  These polymers extend the 
contact time of the drug with the biological tissues and 
improve ocular bioavailability. Most commonly used 
polymers in ocular gels are gellan gum, alginic acid, 
xyloglucan, pectin, chitosan, poloxamer, gellan gum, 
sodium alginate[16]. 
 Advantages  
 1. Increase contact time. 
 2. Greater storage stability.  
Disadvantages  
1.  Blurred vision but less then ointment. 
 2.  Poor patient compliance.  
Recent work done:  A new eye gel containing sodium 
hyaluronate and xanthan gum for the management of 
posttraumatic corneal abrasions.   
Francesco Faraldi et al investigates the effects of an 
ophthalmic gel containing sodium hyaluronate and 
xanthan gum in addition to the antibiotic netilmicin in 
the management of traumatic corneal abrasions[17].Gel 
formation is an extreme case of viscosity enhancement 
through the use of viscosity enhancers. Instead of 
giving multiple doses in case of solutions the dosing 
interval can be reduced in case of gels Cellulose acetate 
phthalate dispersion constituted a microreservoir 
system of high viscosity. Poloxamer 407 is used as an 
ophthalmic vehicle for pilocarpine delivery and found 
that the gel formation enhances the activity of 
pilocarpine. Timolol maleate form thermo gelling drug 
delivery system composed of cellulose ether 
ethylhydroxylethylcellulose.The effect of Flurbiprofen, 
which is a NSAID, formulated in Pluronic F-127 and 
carbopol 940. Gelrite is a polysaccharide which is also 
known as gellan gum. It forms a clear gel in the 
presence of mono or divalent cations. The high 
viscosity of the gel, however, results in blurred vision 
and malted eyelids which substantially decreases 
patient acceptability. Sterilization is another drawback 
for large scale production[2]. A number of workers 
reported that gels vehicles can prolong the corneal 
contact time of many drugs administered by topical 
ocular route, thus prolonging duration of action and 
enhancing ocular bioavailability of drugs[19] 
Noval approaches towards ophthalmic drug 
delivery  
In situ forming gels 
 Ophthalmic in situ gel system was developed in 1980s, 
this type of drug delivery is most widely used it is 
reducing the drainage of the drug from cornea due to 
increase viscosity hence bioavailability automatically 
enhanced. In-situ gelling system can be effect by 
temperature, pH or ion activation[16] These 
preparation gave the better release property of a drug 
over a long period of time in the rabbit’s eye as 
compared to conventional eye drops[20]. Ophthalmic 
in situ system basically found in liquid form but they 
undergo sol to gel phase transition as they are 
administer into the eye due to a particular stimulus. 
After becoming a gel, these remain for a much higher 
extent in the eye as compared to the conventional 
dosage forms[21]. 
Method of preparation of in-situ ocular gel  
Methods  
Cold Method  
HEC was dissolved in water was added to Pluronic 
solution (prepared by dispersing Pluronics over the 
distilled water with continuous stirring (500rpm) and it 
is kept in refrigerator (4 degree) until the Pluronics 
dissolves (Magnetic stirrer) (24Hour)  
                                                               
Mixed both solution @300 rpm on magnetic stirrer, 
500mg drug solution was prepared by dissolving in 
water was prepared and added to above solution.  
 
0.02% Benzalkonium chloride solution was added to 
above solution as preservative and the pH was adjusted 
to 7.4 using 0.5M NaOH, which is then sterilized in 
Autoclave @ 121 degrees for 20 minute[9] 
This is a system were the formulation behave like 
solution form, which changes the behavior to gel when 
it is instilled into the eye. 
Occular Insert  
This novel ophthalmic drug delivery as they show a 
much higher extent of controlled, sustained drug 
release as compared to the conventional forms[18]. 
Ocular insert are solid and semi solid dosage form 
placed into the conjunctival sac. Ocular inserts are 
aseptic, thin, multilayered, drug loaded an efficient 
drug concentration within the intended tissues[22] - 
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Dexamethasone, Pilocarpine nitrate, Tropicamide and 
Timolol Maleate are some example of ocular insert[23] 
 
Microemulsion  
 Micro emulsions are stable dispersions of water and 
oil by using a surfactant and co-surfactant in a manner 
to reduce interfacial tension. Selection of aqueous 
phase, organic phase and surfactant/co-surfactant 
systems are critical parameters which can affect 
stability of the system[17]. These types of ocular drug 
delivery have an advantage of very high 
thermodynamic stability, increase solubility, and 
improved corneal permeation; hence improve the ocular 
bioavailability of the drug[5] .Micro emulsions have a 
transparent appearance, with thermodynamic steadiness 
and a small droplet size in the dispersed phase 
(aqueous and non aqueous phase) (<1.0μm). Due to 
their intrinsic properties and specific structure micro 
emulsions are an interesting substitute to ophthalmic 
formulation[14]. Micro emulsion showed the greatest 
miotic response and duration of action, indicating high 
ocular bioavailability. Various micro emulsion 
formulations for ophthalmic use such as timolol, 
sirolimus, and chloramphenicol were formulated with 
improved stability, solubility, and bioavailability.  
Nanosuspension  
Nano suspensions have proceeded as a favourable 
procedure for the efficient delivery of hydrophobic 
drugs delivery they are not only enhanced the rate and 
extent of ophthalmic drug absorption but also the 
intensity of drug action with significant extended 
duration of drug effect[24].Nano suspensions are 
poorly water-soluble drug suspended in an appropriate 
dispersion medium stabilized by surfactants. 
Nanosuspension has an advantage to improved 
solubility of the drug, enhanced bioavailability, and 
reduced irritation to the eye. Results indicated that the 
nano suspension has shown greater anti-inflammatory 
activity when compared with microsuspensions[5].The 
two technique, media milling and high pressure 
homogenization  are  have been used commercial 
preparation of nanosuspension[17]. 
LIPOSOMES: Liposome’s are multilamellar or 
unilamellar lipid vesicles made up of natural lipids and 
about 25 –10 000 nm in diameter. Liposomes can be 
formulated by sonication of dispersion of 
phospholipids, reverse phase evaporation, solvent 
injection and detergent removal or calcium induced 
fusion method. These formulations are mainly 
composed of phosphatidylcholine and other 
constituents such as cholesterol and lipid-conjugated 
hydrophilic polymers[25]. 
 Phospholipids used Phosphotidylcholine, Phosphotidic 
acid, Sphingomyline, Phosphotidyl-eserine, 
Cardiolipine. Liposomes are Non-toxic, Biodegradable 
and biocompatible in nature. Liposomes can bind 
closely on the eye surface to increase the residence 
time and thus enhance drug absorption and 
bioavailability[22] 
Niosomes 
 Ocular niosomes are nonionic surfactant vesicles that 
used in the delivery of hydrophobic or amphiphilic 
drugs.Niosomes is developed to avoid the limitations 
od liposomes as they are chemically entrap both 
hydrophobic and hydrophilic drugs[26]. They do not 
require special handling techniques for preparation and 
they are non toxic. Niosomes are non-ionic surfactant 
based multilamellar (>0.05µm), small unilamellar 
(0.025-0.05µm) or large unilamellar vesicles (>0.1µm) 
in which an aqueous solution of solute(s) is entirely 
enclosed by a membrane resulted from organization of 
surfactant macromolecules as bilayers. The advantage 
of niosomes are Better patient compatibility and better 
therapeutic effect than conventional[17].The 
characterization of niosomes are ,biodegradability, 
biocompatibility, nonimmuno -genicity and absence of 
various drawbacks related with liposomes, such as high 
cost and the fluctuating purity troubles of 
phospholipids[22] 
Nanoparticle 
 Nanoparticles are solid, submicron, colloidal particles 
made up of biodegradable polymer that combines the 
capabilities of stimulus response and molecular 
recognition hold a pronounced aptitude in ocular drug 
delivery and the ranging in dimension from 10 to 1000 
nm. In ocular nanoparticle the drug molecules are 
present in dissolved, entrapped, adsorbed or covalently 
attached form[22]. Bioavailability can be enhance by 
using carriers, in this system the drug gets bind to these 
carrier molecules and they provide a much higher 
absorption and penetration rate in the 
eye[18].Ophthalmic nanoparticle have been mainly 
produced by emulsion polymerization method for drug 
liberation. In this process a scantily soluble monomer is 
dissolved in the continuous phase which can be 
aqueous or organic. Polymerization is started by 
chemical instigation or by irradiation with gamma rays, 
ultra violet or visible light. The resources that have 
been mainly used fur ophthalmic nanoparticles are 
polyalkyl cyanoacrylates. Nanoparticles are prepared 
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by using bioadhesive polymers to provide sustained 
effect to the entrapped drugs[27].Polymers are used in 
nanoparticles are (PLAs), polycyanoacrylate, poly (d,l-
lactides), natural polymers can be used effectively for 
efficient drug delivery to the ocular tissues[14] 
Dendrimers 
Dendrimers, a nanoparticle based drug delivery system, 
hold a lot of implementations in pharmaceuticals such 
as improving the solubility of miserably soluble drugs, 
improving the delivery of DNA and oligonucleotides, 
targeting drug at specific receptor site, and possess the 
ability to mimic as carrier for the evolvement of drug-
delivery systems The utilitization of aqueous PAMAM 
dendrimers has been revealed to be of importance in 
the ocular route. In fact, PAMAM dendrimers 
displayed physicochemical attributes (pH, osmolality, 
viscosity) that are congruous with ocular 
formulations[22].Dendrimers can successfully used for 
different routes of drug administration and have better 
water-solubility, bioavailability and 
biocompatibility[17]. Dendrimers provide solutions to 
some complex delivery problems for ocular drug 
delivery. Some recent research is dendrimers for ocular 
drug delivery include PAMAM dendrimers that were 
studied by Vandamme and Brobeck as ophthalmic 
vehicles for controlled delivery of pilocarpine and 
tropicamide to the eye. PAMAM dendrimers with 
carboxylic or hydroxyl surface groups, have been 
reported in increasing residence time and enhancing 
bioavailability of pilocarpine in the eye. In the New 
Zealand albino rabbit model, the residence time of 
pilocarpine in the eye was increased by using 
dendrimers with carboxylic or hydroxyl surface groups. 
These surface-modified dendrimers were predicted to 
enhance pilocarpine bioavailability[22]. 
Conclusion 
Ocular drug delivery systems provide local as well as 
systemic delivery of the drugs. In conclusion an ideal 
ophthalmic drug delivery system include,  In situ gel 
forming, ocular insert, micro emulsion, niosomes, 
nanoparticals, nanonsuspension, liposomes, dendri-
mers. And other conventional ophthalmic dosage form 
such as solution, suspension, emulsion, eye drop, 
ointment, spray, viscous solutions, gels etc. The novel 
advanced delivery systems offer more protective and 
effective means of the therapy for various diseases of 
eyes. Stability is the major improvements are required 
in each system. 
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